Curis raises ~$10M; FY2024 net loss $43.4M; FDA/EMA see path for PCNSL drug

CURIS INC

Gross proceeds ~$10M from sale of 1.97M shares and pre-funded warrants for 2.18M shares, plus common warrants for 8.32M shares at $2.41.
FY2024 net loss $43.4M ($6.88/share) vs $47.4M in 2023; revenue $10.9M vs $10.0M; cash $20.0M at Dec 31, 2024.
Cash runway extended into Q4 2025 with offering net proceeds combined with existing cash.
FDA and CHMP guidance supports potential accelerated/conditional approval for emavusertib in PCNSL; 9 of 13 BTKi-experienced evaluable patients had tumor reduction with 4 CRs.

item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.